It represents a strategic evolution in therapeutic development, moving beyond single-target approaches to multi-receptor agonism
De Barra C, Khalil M, Mat A, ODonnell C, Shaamile F, Brennan K, et al
Genetic instruments for GLP-1RAs Genetic instruments for GLP-1RAs were identified on the basis of previous research [16]
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
At higher doses, absorption consistency becomes critical
Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
